Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
about
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenAromatase inhibitors for treatment of advanced breast cancer in postmenopausal womenSpontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell linesFrom HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cellsTrastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancerc-erbB2 expression predicts tamoxifen efficacy in breast cancer patients.HER-2/neu as a predictive marker of response to breast cancer therapy.Circulating tumor markers in breast cancer: accepted utilities and novel prospects.Role of HER2 gene overexpression in breast carcinoma.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.Tamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cellsPredictive and prognostic markers for invasive breast cancer.Prognostic and predictive value of HER2/neu oncogene in breast cancer.Clinical outcome of adjuvant endocrine treatment according to Her-2/neu status in breast cancer.Downregulation of ER-α36 expression sensitizes HER2 overexpressing breast cancer cells to tamoxifenAssociation between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.HER2 therapy: molecular mechanisms of trastuzumab resistance.Effects of in vivo heregulin beta1 treatment in wild-type and ErbB gene-targeted mice depend on receptor levels and pregnancyPoor-prognosis estrogen receptor- positive disease: present and future clinical solutionsThe development, application and limitations of breast cancer cell lines to study tamoxifen and aromatase inhibitor resistanceThe Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study.Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease.Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancerOverexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer.Signaling Pathway of GP88 (Progranulin) in Breast Cancer Cells: Upregulation and Phosphorylation of c-myc by GP88/Progranulin in Her2-Overexpressing Breast Cancer CellsAKT-aro and HER2-aro, models for de novo resistance to aromatase inhibitors; molecular characterization and inhibitor response studiesSurface plasmon resonance investigations of human epidermal growth factor receptor 2.ELISA for quantitation of serum C-erbB-2 oncoprotein in breast cancer patients.Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway.Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study.Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer.Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer.Chromogenic in-situ hybridization: a viable alternative to fluorescence in-situ hybridization in the HER2 testing algorithm.Reliability of chromogenic in situ hybridization for detecting HER-2 gene status in breast cancer: comparison with fluorescence in situ hybridization and assessment of interobserver reproducibility.HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab.
P2860
Q24239985-52236739-D23C-4E5E-AB39-A3796F27E856Q24246391-10EBCA65-752E-4021-A3DC-1B9D269FC82CQ24293655-5A2DDFA2-FF6B-4F20-A450-9786479F7B8DQ24682910-1EFDFC3D-FC2B-46AE-87A8-EAAFA6D6DACDQ24795614-21D5E755-E75F-4092-837F-ADA5BE126B8EQ33538427-42D364C7-BA0D-438A-87DE-5664D564577BQ33538428-56120979-9281-44E9-A598-A9BBF8DC92D6Q33538453-7850D5C0-B6E5-4C88-A2CC-95EA4D7C1BF6Q33810080-F356F785-1130-4F43-A02A-1414E2BDAD06Q33931164-7E18E05F-2C0E-4A9C-8285-858CA17E9A44Q34016364-F4BADB3A-29AA-43DB-91F0-E80A0A365053Q34156192-93A4113C-3737-43BE-B96D-E90DC74C037EQ34612314-731F5194-D55B-424B-A4BF-9F5A9A62138BQ34954864-73281FB1-C92F-4B24-8358-C6C0DA628D83Q34999423-DC0AA63A-815A-421B-BAD4-9A2C996E0B0DQ35402408-62C4ED37-891F-4159-9A2B-1C279F7B00DAQ35588592-5EE5A499-D991-454A-BA0B-A7CBC42B197DQ35633712-301A7669-2FFE-4F5F-89A9-9EABFFC7F282Q35842131-86467762-C9CA-42CC-8D7A-966A0A05EEEDQ35949291-749DE18E-D481-48D6-91AA-1385B324C0F2Q36013029-67E902A6-CC70-4D5C-8483-6E4B5590A722Q36092023-9C2387DD-2006-4507-B03E-1F768FC6D75BQ36458767-B0239FFF-3E15-4E2E-9455-F42FBD5E348CQ36615272-0BCF1CE6-8B29-46CB-B31D-BD0BF7A8E586Q36615792-7A10FB82-0AB6-4710-A34E-E0076FB7A92BQ36617556-CD0DA965-FFFD-40B7-B2D9-9B4096A86D83Q36878094-F399D361-91FD-45CE-84C4-AF53558A551AQ37247518-1254F7EC-3731-45E5-95B1-C9D2EDA348D7Q40227424-73902FB4-EA31-404E-A655-DBA7F5584ACAQ40634215-5A057FD8-4CA8-4545-ABF0-7AAA468340E2Q40635044-B0EA6425-7EE0-4832-8388-3E328E5395F2Q40735449-8AD0A3FB-1755-48D0-91E2-8DACE0954FB4Q44043976-1ABEA75D-C1E5-414B-83DB-B551129EDB2EQ44104081-1FFD4715-94B2-4DCA-A32F-DCF3CB79073CQ46639338-31EB3D29-C022-4306-AA9D-319A3B7DEE9CQ47394260-5B455A48-49D4-4DF7-9232-9A8648FAD3C0Q51953747-F3B5CABE-4193-425B-9CFA-6E91ADB068A7Q52976761-039CDC77-04A3-479A-92BD-2694ADCA9770Q55090683-466D8617-38F1-47B7-B1F0-E36D468C8119
P2860
Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@en
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@nl
type
label
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@en
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@nl
prefLabel
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@en
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@nl
P2093
P1476
Elevated serum c-erbB-2 antige ...... mone therapy of breast cancer.
@en
P2093
H Grossberg
V M Chinchilli
Y Teramoto
P304
P356
10.1200/JCO.1995.13.5.1129
P407
P577
1995-05-01T00:00:00Z